Dogwood Therapeutics (DWTX) Cash from Operations (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Cash from Operations of 4587187.0 for Q1 2026, up 2.04% year-over-year from 4495627.04 in Q1 2025, and down 26.12% quarter-over-quarter from 3637187.0 in Q4 2025.
Dogwood Therapeutics (DWTX) Cash from Operations (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Cash from Operations for 7 consecutive years, with 4587187.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 2.04% year-over-year to 4587187.0; the TTM figure through Mar 2026 stood at 15523284.0 (down 23.83% YoY), while the FY2025 annual figure was 15618651.0, down 77.67% from the prior year.
- Cash from Operations eased to 4587187.0 in Q1 2026 per DWTX's latest filing, from 3637187.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 742414.0 in Q2 2023 and bottomed at 6131508.0 in Q4 2024.
- Historically, Cash from Operations has averaged 2666760.53 across 5 years, with a median of 2656017.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Operations surged 79.7% — and 2025, when it tumbled 399.52%.
- Dogwood Therapeutics' Cash from Operations stood at 2671410.0 in 2022, then surged by 45.0% to 1469171.0 in 2023, then sank by 317.34% to 6131508.0 in 2024, then soared by 40.68% to 3637187.0 in 2025, then decreased by 26.12% to 4587187.0 in 2026.
- Business Quant data shows DWTX's Cash from Operations at 4587187.0 in Q1 2026, 3637187.0 in Q4 2025, and 3272792.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | -3.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.59 Mn |
| Mar 31, 2026 | -4.59 Mn |
| Dec 31, 2025 | -3.64 Mn |
| Dec 31, 2025 | -3.64 Mn |
| Sep 30, 2025 | -3.27 Mn |
| Sep 30, 2025 | -3.27 Mn |
| Jun 30, 2025 | -4.03 Mn |
| Jun 30, 2025 | -4.03 Mn |
| Mar 31, 2025 | -4.68 Mn |
| Mar 31, 2025 | -4.68 Mn |
| Dec 31, 2024 | -6.13 Mn |
| Dec 31, 2024 | -6.13 Mn |
| Sep 30, 2024 | -910,137.00 |
| Sep 30, 2024 | -910,137.00 |
| Jun 30, 2024 | -811,746.00 |
| Jun 30, 2024 | -811,746.00 |
| Mar 31, 2024 | -937,414.00 |
| Mar 31, 2024 | -937,414.00 |
| Dec 31, 2023 | -1.47 Mn |
| Dec 31, 2023 | -1.47 Mn |